The Gordon and Betty Moore Foundation is pleased to announce a new funding opportunity as a part of its Diagnostic Excellence Initiative. The initiative aims to reduce harm from erroneous or delayed diagnoses, reduce costs and redundancy in the diagnostic process, improve health outcomes and save lives. The foundation is soliciting novel ideas and approaches for developing new clinical quality measures to improve diagnosis, specifically targeting three major categories of disease: acute vascular events, infections, and cancer.
Successful applicants will receive funding for $250,000-$500,000 each for projects completed over 18 months. View examples of our latest projects already funded in measure development. This is the fourth round of funding for our quality measure work; this round will prioritize projects related to the development of MIPS (Measure-based Incentive Payment Program) Measures and/or the MIPS Value Pathways (MVPs) and projects using Qualified Clinical Disease Registries. However, we will continue to consider other measure concepts and data sources.
The Diagnostic Excellence Initiative addresses a pressing need to improve diagnostic performance. Over the last few decades, significant progress has been made in medication safety and therapeutics, but work has been slow to address diagnosis. Twelve million Americans experience a diagnostic error each year, and it is likely that each of us will experience a diagnostic error in our lifetime. Delayed or missed diagnoses result in delays in treatment, allow undiagnosed conditions to persist or even progress and worsen outcomes. The development of clinical measures in diagnosis will provide clinicians and medical institutions the ability to track and measure their success and failure rates, giving them an opportunity to solve deficiencies and implement innovations to improve.
Applications will be accepted online beginning February 22 and will be reviewed on a rolling basis up to May 16, 2022.
a) Eligible applicants
Applicants should have an affiliation with an institution or sponsoring organization, including but not limited to academic institutions, health care delivery systems, medical and clinical specialty societies, patients and patient advocacy groups, medical liability and risk management organizations, independent research organizations, electronic health record vendors, and others with interest and/or expertise relevant to diagnosis measure development.
Successful applications will describe teams and partnerships that include a multidisciplinary group of experts, including clinicians with content expertise, individuals with appropriate analytic expertise (data science, statistics, measure development) and persons with experience using relevant data sources. An individual may satisfy more than one of these areas of expertise. Measure development expertise is helpful but not a requirement for funding.
b) Eligibility criteria
Applicants must be familiar with the U.S. health care system and have grant outputs feasible for implementation in the U.S.
Suitable measure concepts must be based on existing scientific evidence and/or clinical guidelines, not new or as yet untested diagnostic tests.
Our scope of funding is not directed at any of the following:
(1) development or evaluation of new diagnostic tests, products, or devices;
(2)development of new clinical guidelines or clinical prediction rules or clinical decision support, or
(3)clinical investigations designed to test a hypothesis.
Examples of previously funded projects can be viewed on the Moore Foundation website at Moore.org (see Third cohort of patient care grantees develop ideas for improving diagnosis, Second cohort aim to develop novel clinical quality measures to improve diagnosis, and New projects aim to develop clinical quality measures to improve diagnosis ).
Projects will be awarded amounts varying from $250,000 to $500,000 for work done over 18 months.
